Eton Q1 revenue $17.3M (+117% YoY); product sales $14.0M (+76%); Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M

Eton Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.06 vs consensus $0.09 ▼ miss (-165.4%)

Q1 2025 product sales $14.0M, 76% growth YoY; 17th straight quarter of sequential growth.
GAAP net loss $(0.06) per share; Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M.
Relaunched INCRELEX (ultra-rare pediatric endocrinology) and GALZIN (Wilson disease); ET-400 NDA PDUFA May 28.
Submitted NDA for ET-600 (desmopressin oral solution) after positive pivotal study; expects 10-month FDA review.
Cash $17.4M; generated $2.1M operating cash flow; expects to exit 2025 at ~$80M annual revenue run rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.